Mayo Advancing Research Equity in ADRD Study in Jacksonville(MAREAS-Jax)

梅奥在杰克逊维尔推进 ADRD 研究中的研究公平性 (MAREAS-Jax)

• 批准号: 10729787
• 负责人: Minerva Maria Carrasquillo
• 金额: $ 54.78万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-15 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10729787
• 关键词: Address; Advisory Committees; African American population; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; American; Amyloid; Amyloid beta-42; Biological; Biological Factors; Biological Markers; Blood; Blood Vessels; Brain; Censuses; Clinic; Clinical; Cognitive; Committee Members; Communication; Communities; Community Participation; DNA; Data; Data Collection; Dementia; Development; Disease; Disparate; Education; Equity; Evaluation; Exposure to; FAIR principles; Feedback; Florida; Focus Groups; Genetic; Genomics; Glial Fibrillary Acidic Protein; Goals; Guidelines; Health; Health behavior; High Prevalence; Hispanic; Hispanic Populations; Individual; Infrastructure; Institution; Investments; Knowledge; Latino; Latino Population; Life Style; Light; Link; Longevity; Measurable; Measures; Medical; Modification; Molecular; Molecular Profiling; Molecular Target; Multiomic Data; Nerve Degeneration; Not Hispanic or Latino; Outcome; Participant; Phase; Plasma; Policies; Population; Positron-Emission Tomography; RNA; Recommendation; Reporting; Research; Research Personnel; Risk; Risk Factors; Risk Reduction; Sampling; Social Environment; Social Processes; Standardization; Systems Biology; Time; United States; United States National Institutes of Health; bilingualism; biomarker identification; biomarker signature; blood-based biomarker; brain health; burden of illness; caucasian American; cerebrovascular; cohort; comorbidity; data analysis pipeline; data sharing; dementia risk; design; disparity elimination; disparity reduction; empowerment; health determinants; health disparity; imaging biomarker; improved; individualized feedback; infrastructure development; modifiable risk; multiple omics; neurofilament; neuroimaging; novel; outreach; personalized strategies; pre-clinical; programs; recruit; risk mitigation; social; social health determinants; tau Proteins

PROJECT SUMMARY/ABSTRACT Hispanics/Latinos (HL) and African Americans (AA) represent a rapidly growing proportion of the United States population (18.7% HL, 12.4% AA - US 2020 Census) who remain critically underrepresented in research of Alzheimer disease (AD) and AD-related dementia (ADRD), despite a 1.5-2-fold higher prevalence of dementia (vs non-Hispanic-white Americans). Underrepresentation in AD/ADRD research exacerbates health disparities and challenges the development and implementation of efficacious and safe risk-reduction strategies for AD/ADRD in HL/AA. Genetics do not fully explain disparate AD/ADRD risk, highlighting a fundamental knowledge gap concerning how genomic factors interact with comorbidities and lifespan exposures to Structural/Social Determinants of Health (SDoH; the “exposome”) to inform AD/ADRD risk. There is a critical need to identify clinical, SDoH, and biological factors that contribute to disparate risk in HL/AA; establish the relationship between exposures underlying AD/ADRD outcomes; use this information to mitigate disparities in AD/ADRD burden through education and risk factor modification; and broadly disseminate this information to inform the development of effective biomarkers and therapies. The Mayo Advancing Research Equity in ADRD Study in Jacksonville (MAREAS-JAX; Spanish for tides) will address this need. Aim 1 will advance recruitment of HL/AA cohorts (UH2) by developing/deploying outreach, recruitment, and engagement best practices for HL/AA in Jacksonville, Florida, through a bilingual (English-Spanish) research team, supported by community ambassador teams (CAT) and an external advisory committee (EAC) including experts in SDoH and AD/ADRD research. Aim 2 will identify relevant measures of AD/ADRD burden (UH2►UH3). SDoH, cognitive, clinical, and blood-based biomarker measures associated with cerebrovascular, amyloid, and tau burden, will be collected through comprehensive/culturally appropriate annual assessments and integrated with multi-omics data, structural (MR) and molecular (amyloid and tau) PET neuroimaging obtained at study entry, and every 2 years thereafter to identify modifiable dementia risk factors, blood-based biomarkers, and molecular signatures of AD/ADRD burden. Data collection will be standardized with input from EAC members to optimize scalability and promote sample/data sharing. Aim 3 will provide meaningful individualized feedback (UH3) to participants through a Brain Health Report detailing actionable risk factors and recommendations to mitigate intraindividual AD/ADRD burden. Aim 4 will use multi-omics measures to identify molecular targets and signatures that interact with the exposome and associate with AD/ADRD burden in HL/AA (UH3) using a systems biology approach with validated analytic pipelines and prioritizing broad data sharing following NIH’s findability, accessibility, interoperability, and reusability guidelines. In this way, MAREAS-Jax will chart the currents that drive disproportionate participation in AD/ADRD research and disparate AD/ADRD burden and will inform the design and implementation of strategies to shift these tides in Northeast Florida and beyond.

项目摘要/摘要 西班牙裔/拉丁美洲人（HL）和非洲裔美国人（AA）代表了美国迅速增长的比例 人口（18.7％HL，12.4％AA -2020年普查）在研究方面的总额不足 阿尔茨海默氏病（AD）和与AD相关的痴呆（ADRD），尽管痴呆症患病率高1.5-2倍 （vs非西班牙裔美国人）。 AD/ADRD研究的代表性不足加剧了健康分布 并挑战开发和实施高效，安全的降低风险策略 hl/aa中的广告/adrd。遗传学不能完全解释不同的广告/ADRD风险，强调了基本 知识差距关于基因组因素如何与合并症和寿命暴露于 卫生的结构/社会决定因素（SDOH；“ Exposome”），以告知AD/ADRD风险。有关键 需要识别临床，SDOH和生物学因素，这些因素导致HL/AA的不同风险；建立 广告/ADRD结果的暴露之间的关系；使用此信息来减轻分布 通过教育和风险因素修改，AD/ADRD BURNEN；并将这些信息广泛传播给 告知有效的生物标志物和疗法的开发。 Mayo在ADRD中推进了研究平等 在杰克逊维尔（Mareas-Jax；西班牙潮汐）学习将满足这一需求。 AIM 1将推进招募 通过开发/部署外展，招聘和参与的最佳实践，用于HL/AA队列（UH2） 在佛罗里达州杰克逊维尔的HL/AA通过双语（英语）研究团队，得到社区的支持 大使团队（CAT）和外部咨询委员会（EAC），包括SDOH和AD/ADRD的专家 研究。 AIM 2将确定AD/ADRD Burnen（UH2►UH3）的相关度量。 SDOH，认知，临床和 将收集与脑血管，淀粉样蛋白和Tau Burnen相关的血液生物标志物测量 通过全面/文化适当的年度评估，并与多词数据集成 在研究进入时获得的结构（MR）和分子（淀粉样蛋白和TAU）PET神经影像学，每2年 此后，以确定可修改的痴呆危险因素，基于血液的生物标志物和分子特征 广告/adrd负担。数据收集将通过EAC成员的输入进行标准化，以优化可伸缩性和 促进样品/数据共享。 AIM 3将为参与者提供有意义的个性化反馈（UH3） 通过大脑健康报告，详细介绍了可操作的风险因素和建议，以减轻内在性 广告/adrd负担。 AIM 4将采用多摩学措施来识别分子靶标和标志 使用系统生物学方法与HL/AA（UH3）中的AD/ADRD Burnen合作，并与AD/ADRD Burnen合作 经过验证的分析管道，并在NIH的可访问性，可访问性， 互操作性和可重复性指南。这样，Mareas-Jax将绘制驱动的电流 不成比例地参与广告/ADRD研究和不同的广告/ADRD燃烧，并将告知设计 并实施在佛罗里达州东北部及其他地区转移这些潮流的策略。